Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by GrahamBon Mar 04, 2021 5:30am
152 Views
Post# 32712625

RE:RE:RE:RE:Understanding Yutian Medical Shanghai Deal

RE:RE:RE:RE:Understanding Yutian Medical Shanghai Deal
Yajne wrote: wounded...I have heard Cathie Wood (ARK) comment on 'disruptive' techs like PYR, and I believe in a lesser way VPT fits the same 'disruptive' bill. She suggests that disruptive tech requires much 'forward thinking' to determine what future earnings might be, rather that projecting forward any 'trailing earnings' for a company, the traditional way to measure a company going forward. In fact she suggests that the folks living in the 'old world' of trailing indicators are at at extreme risk in the new world of technologies emerging. I think VPT fits the description perfectly. While folks like you (and GrahamB) attempt to provide doubt to folks here based on historical and current cash flow, you are completely missing the potential that market disruptive companies bring to the table, and that is HUGE future earnings, or perhaps even buyout before they can generate those huge earnings. It's a case of backward (trailing) focussed folks versus those that are forward looking. GrahamB attemps to put a traditional 'trailing earnings' spin on VPT's story. He's WRONG on VPT

Interesting back-and-forth here, and great to see people actually discussing the company.

Now, about whether reviewing the financials for evidence of sales, revenue, and ultimately profit which of course are looking backwards are relevant for a company like this, versus forward-looking statements about potential sales, given what is purported here to be disruptive technology.....

First, understanding financials, is important , as cash is the oxygen that allows a company to breathe and survive.  Just looked back to the last year, when the company was not treating because they were in solvent. 

No cash-=no business.
Now there have been financing recently as a life line, but it isnt sustainable and a company needs to generate revenue and profit to survive and grow.
So for ME-I will wait until I see this either in finacials or a verifiesd report in real time.
But statements of what could be? A multi billion diollar company as stated by m,any hgere and in videos in the past?
Nah-been there done that.


To the point...Sales are also critical, because they do indicate adoption of a “disruptive technology”, since physicians would be committing to a purchase because they believe in the technology.  Versions of this product has been around for 10 years, and that still has not happened.
 
Furthermore, the concept of disruption is one  I am certainly familiar with, however I am also aware is the term is frequently misapplied and misunderstood. In fact, the authors of this have said:,
In our experience, too many people who speak of “disruption” have not read a serious book or article on the subject. Too frequently, they use the term loosely to invoke the concept of innovation in support of whatever it is they wish to do

”https://hbr.org/2015/12/what-is-disruptive-innovation
This from the creators of the term at Harvard.

I know that people don’t like long posts here and I won’t go on any further about this, but read this article and you will see, that the concept of disruption is often misapplied, and VPT, at this point, has not met the criteria being a disruptive technology that they outline, all IMO.(The purchases at this technology will ultimately be the ones to decide whether or not this is true and that will be measured in purchases or sales)

It is convenient, but dangerous, to keep looking forward, and justifying the fact that you don’t have any revenues or sales because you say you are  disruptive.

Companies that are truly disruptive, actually disrupt, because they are taking over customers, and changing the way the business happens. It’s been 10 years, and the trajectory here is flat.

Also, AI medicine is booming. It’s also taking off in echocardiography, and it’s been even encouraged by the FDA.

https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device

 Remember, this technology was not invented by GA, but by University of Washington, and that patent has run out. Others are adopting AI where it is useful, even GE, mentioned by GA in the recent video , has a division and products that there selling already..
 
GE Healthcare nabbed FDA clearance for its artificial intelligence-powered cardiovascular ultrasound system, designed to help automate and standardize echocardiogram exams. The Ultra Edition package for the company’s line of Vivid ultrasounds incorporates learning algorithms that can automatically detect the points in a 2D image that are used to measure the size of the left ventricle, an important metric in diagnosing and treating heart failure and disease.”
https://www.fiercebiotech.com/medtech/ge-healthcare-s-cardiovascular-ultrasound-ai-nets-fda-clearance

With technology available will they or others develop 3D reconstruction for all chambers?
Dont kniow-but will waitb to see that OR revenue/profits before I invest my cash
Again, just IMO-

<< Previous
Bullboard Posts
Next >>